Premium
High‐dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre
Author(s) -
Boehnke C.,
Reuter U.,
Flach U.,
SchuhHofer S.,
Einhäupl K. M.,
Arnold G.
Publication year - 2004
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2004.00813.x
Subject(s) - medicine , migraine , riboflavin , open label , tertiary care , anesthesia , prophylactic treatment , pediatrics , adverse effect , biochemistry , chemistry
The aim of this study was to investigate the efficacy of riboflavin for the prevention of migraine. An open label study was performed in a specialized outpatient clinic. Patients received 400 mg riboflavin capsules per day. Headache frequency, duration, intensity and the use of abortive drugs were recorded at baseline and 3 and 6 months after treatment. Headache frequency was significantly reduced from 4 days/month at baseline to 2 days/month after 3 and 6 months ( P < 0.05). The use of abortive drugs decreased from 7 units/month to 4.5 units/month after 3 and 6 months of treatment ( P < 0.05). In contrast, headache hours and headache intensity did not change significantly. We could demonstrate a significant reduction of headache frequency following riboflavin treatment. In addition, the number of abortive anti‐migraine tablets was reduced. In line with previous studies our findings show that riboflavin is a safe and well‐tolerated alternative in migraine prophylaxis.